Published in TB and Outbreaks Week, November 3rd, 1997
"This study demonstrated that LTR192G adjuvant can be safely given to adults at potentially adjuvant-active doses," said Michael Oplinger of the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Maryland.
LTR192G is a form of Escherichia coli heat-labile enterotoxin that has been genetically engineered to have extremely reduced toxicity...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.